VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking ...

Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.

Wedbush restated their neutral rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research note ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Program highlights for the fiscal year ended March 31, 2025, along with recent developments, include: Patient with advanced/metastatic end-stage pancreatic cancer who responded to MDNA11 treatment ...

Feeling a little down? Discover how you can boost your happiness and improve your health by harnessing the powerful benefits of endorphins. With easy methods like exercise, laughter, and connection at ...

MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® ...

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

Picture this: It’s 3 PM, and you’re crashing harder than a ... Gymnema sylvestre targets sugar receptors to reduce cravings while supporting pancreatic beta cell function. Bitter melon provides ...

Discover how leaky gut and food sensitivities like gluten and dairy can trigger anxiety through inflammation and disruption ...